| ²é¿´: 1242 | »Ø¸´: 107 | |||
ADTechnology
|
[É̼ҹ©Ó¦]
Magna m6A RNA¼×»ù»¯ÃâÒß³ÁµíÊÔ¼ÁºÐ-ÌØ¶¨Î»µã¼ì²â
|
|
ÏÞÁ¿ x ÕÅ
Âú x ¿ÉʹÓã»ÓÐЧÆÚ x Ì죻¹ýÆÚ¿ÉÍË |
ÄÚÈÝ
Õë¶ÔÌØ¶¨Î»µãµÄ m6A RNA¼×»ù»¯£¬È«Çò¶¥¼¶¼ì²â·½·¨¡£¾ßÌå²Î¿¼ÈçÏ£ºMagna m6A RNA¼×»ù»¯ÃâÒß³ÁµíÊÔ¼ÁºÐ-ÌØ¶¨Î»µã¼ì²â »õºÅ£ºA-17-10499 Magna MeRIP™ m6A Kit- Transcriptome-wide Profiling of N6-Methyladenosine ±³¾°×ÊÁÏ£ºN6-methyladenosine (m6A) represents an abundant RNA modification that is conserved across many different species, ranging from plants, to yeast, to mammals. Similar to the 5-methylcytosine (5-mc) modification of DNA, m6A is a reversible chemical modification of RNA. m6A RNA modifications are an emerging topic in controlling cell fate transitions in mammalian embryonic stem cells. m6A is one of the most prevalent modifications on both mRNAs and noncoding RNAs in eukaryotes with an estimated 12,000 m6A sites in over 7,000 genes. The mark is deposited by a heterodimer of methyltransferase-like 3 and 14 (Mettl3 and Mettl14) and can be removed by the RNA demethylase enzymes FTO and ALKBH5. Obesity risk gene FTO encodes the first identified m6A demethylase. Mutations in FTO have been associated with increased risk for obesity and type II diabetes. Recently, impairment of the status of m6A regulation has lead to prolonged expression of Nanog in ES cells and the inability to exit self-renewal stages toward differentiation¡£ ²úÆ·ÃèÊö£ºMethylated (m6A) RNA immunoprecipitation (MeRIP) is a method to monitor the status of m6A and map the location of m6A RNA modifications transcriptome-wide. The Magna MeRIP M6A Kit uses the MeRIP method to enable identification and transcriptome-wide profiling of m6A RNA modifications. In the MeRIP assay, RNA is chemically fragmented into 100 nucleotides or smaller fragments followed by magnetic immunoprecipitation with a monoclonal antibody toward m6A. After immunoprecipitation, isolated RNA fragments can be subjected with qRT-PCR or RNA sequencing (MeRIP-seq). The streamlined protocol is easy to process and can produce results with high SN ratios¡£ ²úÆ·ÌØµã£º 1¡¤Complete collection of MeRIP valiidated reagents to streamline the MeRIP method£» 2¡¤High signal to noise ratios using high affinity m6A monoclonal antibody and A/G magnetic beads £» 3.Stem cell validated£» 4.The Magna MeRIP M6A Kit provides sufficient reagents for 10 MeRIP reactions using 5 ¦Ìg of mRNA or 5 MeRIP reactions when 300 ¦Ìg of total RNA is used£» 5.Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals¡£ ±£´æ½¨Ò飺ÔÚ½ÓÊÕµ½°¬µÂ¼Ä³öµÄÊÔ¼ÁºÐºóÇë°´ÕÕ˵Ã÷Ê齨Ò飬ʹÓò»Í¬µÄ±£´æÌõ¼þ»òζÈÀ´±£´æÊÔ¼ÁºÐÄÚ×é·Ö¡£ Ïà¹ØµÄ×ÊÁÏ£¬ÇëÏÂÔØ²Î¿¼¸½¼þ¡£ |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : A-17-10499-Magna_m6A_RNA¼×»ù»¯ÃâÒß³ÁµíÊÔ¼ÁºÐ-ÌØ¶¨Î»µã·ÖÎö.pdf
- ¸½¼þ 2 : A-P-9005-m6A_RNA¼×»ù»¯¶¨Á¿¼ì²âÊÔ¼ÁºÐ£¨±ÈÉ«·¨£©.pdf
- ¸½¼þ 3 : SC-°¬µÂ¿Æ¼¼-¾øÕÐÔÚÉí£¡×ß±éÌìÏ£¡ÕÆÎÕ±í¹ÛÒÅ´«Ñ§Ç°ÑزúÆ·Ñо¿¹¤¾ß£¡.pdf
- ¸½¼þ 4 : SC-°¬µÂ¿Æ¼¼-ÃÈ»õ£¡±¼Åܰɣ¡£¡RNA¼×»ù»¯Ê±´úÀ´ÁË£¡£¡£¡.pdf
2017-02-09 09:17:27, 1.18 M
2017-02-09 09:18:02, 1.25 M
2017-02-09 09:18:51, 3.81 M
2017-02-09 09:18:59, 2.4 M
» ²ÂÄãϲ»¶
271²ÄÁϹ¤³ÌÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
281Çóµ÷¼Á£¨0805£©
ÒѾÓÐ16È˻ظ´
304Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁϹ¤³Ìר˶µ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸Ìì´ó²ÄÁÏÓ뻯¹¤£¨085600£©×Ü·Ö338
ÒѾÓÐ4È˻ظ´
085700×ÊÔ´Óë»·¾³308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Çó²ÄÁϵ÷¼Á
ÒѾÓÐ8È˻ظ´
294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸¼ªÁÖ´óѧ²ÄÁÏѧ˶321Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Î÷ºþ´óѧ¹¤Ñ§ÔºÖÇÄÜ΢ÐÍ»úÆ÷ÈËʵÑéÊÒ²©Ê¿ºóÕÐÆ¸ÆôÊÂ
+4/228
˫һÁ÷ÄϾ©Ò½¿Æ´óѧÕмÆËã»ú¡¢AI¡¢Í³¼Æ¡¢ÉúÎïÐÅÏ¢µÈ·½Ïò26Äê9ÔÂÈëѧ²©Ê¿
+1/97
¼ÃÄÏ´óѧÁÖÐã¾ê½ÌÊÚÕÐÊÕ²ÄÁÏÀ಩ʿÉú
+1/87
¸£½¨Ê¦·¶´óѧÕÐÊÕ2026Ä껯ѧ¡¢²ÄÁÏ˶ʿ3-4Ãû
+1/80
Õã½Å©ÁÖ´óѧÕÐÊÕµ÷¼Á
+1/80
Æ®ÔÚÃÀ¹ú£¬ÓеãÏë¼Ò
+1/57
»¶Ó½»Á÷×Éѯ
+1/37
°Ä´óÀûÑÇÎ÷°Ä´óѧ£¨UWA£©ÕŽðÇ¿¿ÎÌâ×éÕÐÊÕÈ«½±²©Ê¿Éú£¨»¯¹¤ÐÂÄÜÔ´·½Ïò£©
+1/26
±¨ÃûͨµÀ¿ªÆôÀ²£¡Õã½ÖÐÒ½Ò©´óѧ¸±Ð£³¤ÍŶÓÕÐÆ¸Ò©Ñ§/ÉúÎïÐÅϢѧµÈ·½Ïò¸ßУ½Ìʦ7Ãû(µØµ
+1/21
ÄϾ©Àí¹¤´óѧ2026¼¶Ë¶Ê¿ÉúÕÐÉú-ÕŹâÆÕ²©µ¼ &˶µ¼
+2/18
¡¾2026²©Ê¿ÕÐÉú/²©ºóÕÐÆ¸¡¿±±¾©º½¿Õº½Ìì´óѧÅ˱ë¿ÎÌâ×顪¡ªAIоƬÉè¼Æ·½Ïò
+1/11
ÁijǴóѧ»¯ÔºÇཷÕÐÊÕ»¯Ñ§Ïà¹Ø×¨Òµµ÷¼ÁѧÉú
+1/7
½ÌÓý²¿³¤½Ñ§Õߺʹ´ÐÂÍŶӷ¢Õ¹¼Æ»®¡±ÈëÑ¡ÍŶÓÕÐÊÕ ²ÄÁÏ£¬»¯Ñ§Ó뻯¹¤²©Ê¿Ñо¿Éú
+1/7
¸£ÖÝ´óѧ¹ú¼Ò¼¶È˲ÅÌÀÓýÐÀ½ÌÊÚ¿ÎÌâ×é2026ÄêÕÐÊÕ¡±ÉêÇ뿼ºËÖÆ¡°´¢ÄÜµç³Ø·½Ïò²©Ê¿Ñо¿Éú
+1/6
¾ü¿ÆÄ³Ñо¿Ôº½ÓÊÕµ÷¼ÁÑо¿Éú
+1/5
¡°»úе¡¢²ÄÁÏ¡±ÕÐÉú
+1/3
323·Ö¿ØÖƹ¤³ÌÇóµ÷¼Á
+1/2
085404 270Çóµ÷¼Á£¬bÇøÇóµ¼Ê¦ÊÕÁô½ÓÊÜ¿çרҵ
+1/1
¡¾2026Äê´º¼¾²¹Â¼¡¿ÏÃÃÅ´óѧÌïÖÐȺԺʿ/Ò׿¥½ÌÊÚÄÉÃ×¹â×ÓѧÍŶÓÕÐÊÕ2026ÄêÈëѧ²©Ê¿Éú
+1/1
ÄÏ·½¿Æ¼¼´óѧ£¨Í¬Î»ËØ£©»¯Ñ§¼°Ó¦Ó÷½Ïò²©Ê¿ºóÕÐÆ¸£¨2Ãû£©
+1/1
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
2Â¥2017-02-09 09:28:41
ADTechnology
¾èÖú¹ó±ö (ÖøÃûдÊÖ)
±í¹ÛÒÅ´«Ñ§×¨Òµ¹©Ó¦ÉÌ
- Ó¦Öú: 12 (СѧÉú)
- ½ð±Ò: 12092.7
- É¢½ð: 1762
- ºì»¨: 1
- Ìû×Ó: 2608
- ÔÚÏß: 49.1Сʱ
- ³æºÅ: 1787705
- ×¢²á: 2012-04-30
- רҵ: ÈËÀàÒÅ´«Ñ§

±í¹ÛÒÅ´«Ñ§£¨m6A RNA¼×»ù»¯¡¢RNA¼×»ù»¯¡¢DNA¼×»ù»¯¡¢DNAôǼ׻ù¡¢DNA¼×õ£»ù¡¢DNAôÈ»ù£©£¬·Ö×ÓÉúÎïѧ£¬ÃâÒßÉúÎïѧ£¨Ò»¿¹¡¢¶þ¿¹£©£¬Ï¸°ûÉúÎïѧ£¬ÊµÑéÒÇÆ÷ѧ£¨ºËËáÌáÆðÒÇ¡¢³¬Î¢Á¿·Ö¹â¹â¶È¼Æ£©µÈµÈ²úÆ·Óë¼¼Êõ·þÎñ
±±¾©ÊвýÆ½ÇøÖйشåÉúÃü¿ÆÑ§Ô°¶«60Ã×°¬µÂÔ°
ÁªÏµÈË: Peter Chen / ÓÊÏä: 1951545998@qq.com / QQ: 1513545070 / µç»°: 0313-5935521 / ÊÖ»ú: 18911529660
3Â¥2017-02-09 09:29:48
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
4Â¥2017-02-09 09:48:15
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
5Â¥2017-02-09 09:50:35
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
6Â¥2017-02-09 09:50:59
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
7Â¥2017-02-09 09:52:18
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
| ¡¤ |
8Â¥2017-02-09 09:55:15
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
9Â¥2017-02-09 09:56:11
¡ï
ADTechnology(½ð±Ò+1): лл²ÎÓë
ADTechnology(½ð±Ò+1): лл²ÎÓë
|
10Â¥2017-02-09 09:59:19


Õë¶ÔÌØ¶¨Î»µãµÄ m6A RNA¼×»ù»¯£¬È«Çò¶¥¼¶¼ì²â·½·¨¡£¾ßÌå²Î¿¼ÈçÏ£º
»Ø¸´´ËÂ¥